Platform Proposed capability

Every candidate would pass written decision gates from botanical source to commercial asset, so weak candidates stop before they become expensive

What each stage would establish, the document it would produce, what would stop a program, and which work would stay in house or go to a partner.

Related: How EUTECNIQ differs · Academy courses

7platform pages

71figures and diagrams

20interactive tools

116evidence labels

184registered claims

Status. EUTECNIQ has no laboratory, staff besides the founder, customers or data. Every capability, phase and partner role here is a proposal.

What the pathway is built to give a customer

Earlier answers. Identity, contaminants and safety first, while a "no" is cheap.
Documents that travel. Each stage ends in a document a buyer can review.
A transferable process. Written so another qualified site can repeat it.

Platform pages

Seven pages explain the method, the quality system and the data layer; select one to open it

The platform section: three themes inside, pages outsideSite structure

Built from the site navigation; tooltips give each page's figure and tool counts.

Bar on each card: evidence labels on that pageVerified dataPeer-reviewedRegulation or guidanceThird-party estimateProposal, partner or riskSimulation or schematic

Method and evidence

How EUTECNIQ differs

Operating models compared, from companies' own documents.

12 figures

Method and evidence

Proposed lab journey

The proposed laboratory, station by station.

7 figures

Method and evidence

Scientific deliverables

The documents each stage would produce.

7 figures2 interactive

Quality

Quality system

One management system over Parts 111, 117 and ISO 17025.

9 figures4 interactive

Quality

Quality and Six Sigma

ISO, cGMP, SQF, SPC, capability and gauge R&R.

11 figures5 interactive

Quality

QbD & control strategy

Critical quality attributes, design space, control.

10 figures4 interactive

Data

Evidence labels on each platform page, by family, counted at build time
Page	Labels	Verified data	Regulation or guidance	Third-party estimate	Proposal, partner or risk	Simulation or schematic
How EUTECNIQ differs	18	7 (39%)	2 (11%)	0 (0%)	7 (39%)	2 (11%)
Proposed lab journey	16	0 (0%)	5 (31%)	0 (0%)	7 (44%)	4 (25%)
Scientific deliverables	9	1 (11%)	1 (11%)	0 (0%)	6 (67%)	1 (11%)
Quality system	20	3 (15%)	3 (15%)	1 (5%)	13 (65%)	0 (0%)
Quality and Six Sigma	15	4 (27%)	1 (7%)	0 (0%)	1 (7%)	9 (60%)
QbD & control strategy	19	1 (5%)	9 (47%)	0 (0%)	7 (37%)	2 (11%)
Digital lab and traceability	19	3 (16%)	10 (53%)	0 (0%)	3 (16%)	3 (16%)

Each customer brings a different question, and each question has a defined document as its answer

One stage-gate logic would serve six kinds of customer. No customer has engaged EUTECNIQ yet.

Which stages each customer would use, and what it would receiveProposed service model

Every deliverable is a technical document, not an FDA certificate, approval or clearance. Contents and limits: deliverables library. Quality targets and controls: quality by design and quality system.

Text version: the question each customer brings and the documents it would receive

Customer	Question they bring	Stages used	What they would receive
Supplement brand or contract manufacturer	Is this ingredient what the supplier says it is, and can we specify and release it reliably?	Identity, characterization	Identity passport, characterization package, supplier qualification package
International ingredient supplier entering the U.S.	What does a U.S. buyer need from us before it can qualify our material?	Source, identity, characterization, regulatory strategy	Supplier qualification package, market-access assessment
Developer of a new dietary ingredient	Is a notification needed, and is our identity and safety evidence sufficient?	Stages 1 to 7	Botanical safety dossier, NDIN support package
Food, beverage or cosmetic formulator	Will this ingredient stay stable and dispersed in our format, and what may we claim in our category?	Characterization, delivery engineering, regulatory strategy	Formulation applications package, delivery technology dossier
Company changing a supplier, site or scale	Is the new lot, site or scale equivalent for its intended use?	Characterization, scale-up	Comparability package, process development and transfer package
Technology or licensing partner	Is there a protectable, commercially useful result, and who would own it?	Commercial	IP and commercialization assessment

Discovery to commercialization

Eight stages and eight gates: each stage has to earn the next one

Stage-gate logic: proceed, loop back or stop at every gateIllustrative schematic

A diagram of decision logic, not a measured attrition rate. The rising cost of decisions along the pathway is qualitative; no figures are implied. Phase labels refer to the proposed facility phases on the facilities roadmap.

A stop at the identity gate costs a few tests; a stop after scale-up costs a pilot campaign. The pathway puts the cheapest decisive questions first.

Explanation, details and sources

Each gate is a written proceed, loop-back or stop decision against criteria fixed before the work starts. Stopping is a normal outcome; the data and the reason are kept for the next candidate.

Why the early gates matter

Specification, identity and quality-control rules drew about half of FDA's Part 111 citations every year from 2019 to 2025

FDA Form 483 citations of 21 CFR Part 111 by subpart, fiscal 2025, and by topic, fiscal 2019–2025FDA inspection data

Source: U.S. FDA, Inspection observations spreadsheets, Foods tab, FY2019–FY2025 (page current as of December 16, 2025), summed by subpart using the eCFR structure of Part 111 (retrieved October 24, 2026). The grouping into four topics is EUTECNIQ's. Counts cover 483s from FDA's electronic inspection tool only; a citation is an inspector's observation, not a finding of harm, and counts are not rates.

Data table

Form 483 citations of 21 CFR Part 111 by subpart and fiscal year (FDA inspection observations, Foods tab)
Subpart (sections)	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
A: General Provisions (111.1–111.5)	0	0	0	0	0	0	0
B: Personnel (111.8–111.14)	44	26	21	28	38	37	53
C: Physical Plant and Grounds (111.15–111.23)	63	24	17	35	27	53	67
D: Equipment and Utensils (111.25–111.35)	82	42	34	45	46	69	75
E: Requirement to Establish a Production and Process Control System (111.55–111.95)	490	290	260	459	423	614	759
F: Production and Process Control System: Requirements for Quality Control (111.103–111.140)	198	112	120	179	169	205	216
G: Production and Process Control System: Requirements for Components, Packaging, and Labels and for Product That You Receive for Packaging or Labeling as a Dietary Supplement (111.153–111.180)	45	28	16	18	37	36	43
H: Production and Process Control System: Requirements for the Master Manufacturing Record (111.205–111.210)	117	91	45	101	92	156	188
I: Production and Process Control System: Requirements for the Batch Production Record (111.255–111.260)	116	115	58	100	97	153	163
J: Production and Process Control System: Requirements for Laboratory Operations (111.303–111.325)	28	6	13	33	23	33	77
K: Production and Process Control System: Requirements for Manufacturing Operations (111.353–111.375)	21	7	10	21	16	30	49
L: Production and Process Control System: Requirements for Packaging and Labeling Operations (111.403–111.430)	41	29	20	37	29	38	37
M: Holding and Distributing (111.453–111.475)	76	41	34	63	72	63	72
N: Returned Dietary Supplements (111.503–111.535)	50	21	19	42	53	48	65
O: Product Complaints (111.553–111.570)	71	35	32	50	48	45	66
P: Records and Recordkeeping (111.605–111.610)	2	4	5	7	3	3	8
All Part 111 citations	1,444	871	704	1,218	1,173	1,583	1,938

Subparts E, F and J cover written specifications, identity testing, quality control and laboratory operations: the questions the first gates would answer.

Stage by stage

For each stage: the objective, the measurements, the gate, the ways it fails and who would do the work

Gate criteria are proposed internal standards. Where a rule sets a legal minimum, the rule is cited.

What lets a candidate through each gate, and what stops itProposed gate criteria

Rule column: 21 CFR sections unless stated. Two orthogonal identity methods, GLP-style pivotal studies and the other gate criteria are EUTECNIQ proposals, not legal requirements.21 CFR 1.511, 101.93(f), 111.70, 111.75, 111.320, Parts 50, 56, 58, 111, 117, 210–211 (eCFR, current to Oct 21, 2026); FDA, NDI identity and safety final guidance (Oct 2026); CITES; Nagoya Protocol (CBD).

The methods behind each gate, and whether they would be in house or with a partnerProposed capability

Phases are the proposed facility phases on the facilities roadmap. Trade statistics used in sourcing are context only (global trade data). Scale-up models: process engineering and scale-up.ISO 22412; ISO 13320; USP <2040>; Brodkorb et al., Nat Protoc 2019;14:991–1014 (INFOGEST); Pouton, Eur J Pharm Sci 2000 and 2006; EFSA Scientific Committee, benchmark dose guidance (2022); Raclariu et al., Phytochem Anal 2018;29:123–128.

Full stage sheets: objective, measurements, instruments, gate, deliverable, regulatory limits, in house or partner

Botanical sourceSupplier qualification file
IdentityIngredient identity passport
Molecular characterizationCharacterization package, draft specifications
Safety and interactionsRisk dossier and testing plan
Delivery engineeringFormulation prototype, delivery dossier
Process scale-upSpecifications with validated methods, tech-transfer file
Regulatory strategyMarket-access assessment, safety package for filings
Commercial ingredient, technology or IPIP and commercialization assessment

01Botanical source

In house · Phase IPartner · in-country audits

Objective. Secure plant material that is legal to trade, traceable to its origin and consistent enough to develop.

Measurements: Supplier documents (origin, harvest or cultivation records, processing steps); legal-status checks; screening tests on several lots for identity and gross contamination; lot-to-lot spread of a few marker attributes.
Instruments and models: Supplier questionnaire and audit protocol; HPTLC (high-performance thin-layer chromatography) screening; a sourcing risk register by species, region and supplier concentration. Trade statistics are context only (see global trade data).
Proceed if: Several representative lots are available with complete documentation, and no legal barrier to collection, export or import exists.
Stop or loop back if: The species is CITES-listed and valid permits are missing.
The source country requires access and benefit-sharing terms (Nagoya Protocol) and none exist.
Material cannot be traced to its origin.
Wild collection has no sustainability plan.
Lots are too variable or contaminated to standardize.
Deliverable: The first part of a supplier qualification package.
Regulatory limits: Supplier documents do not establish identity. A dietary-supplement manufacturer must still test or examine every dietary-ingredient lot for identity (21 CFR 111.75(a)(1)(i)). Importers have Foreign Supplier Verification Program duties, modified for supplements by 21 CFR 1.511. Regulatory requirement
In house or partner: In house (planned, Phase I): sourcing, document review, screening tests. Qualified partners: in-country auditors and agents for foreign sites.

02Identity

In house · Phase IPartner · DNA, NMR

Objective. Confirm the species, the plant part and the absence of plausible adulterants for every lot.

Measurements: Macroscopic and microscopic features; HPTLC fingerprint against authenticated reference material; HPLC or LC-MS marker profile; targeted tests for known adulterants; DNA barcoding of crude plant material where suitable.
Instruments and models: Microscopes, HPTLC, HPLC with diode-array detection, LC-MS (liquid chromatography–mass spectrometry). DNA sequencing and NMR (nuclear magnetic resonance) through external laboratories. Pattern-recognition statistics for fingerprints.
Proceed if: Two independent (orthogonal) methods agree with an authenticated reference, and adulterant screens are negative.
Stop or loop back if: Wrong species or plant part.
An adulterant is detected.
No authenticated reference material exists.
The method cannot separate close relatives.
Deliverable: Ingredient identity passport.
Regulatory limits: The rule requires at least one appropriate identity test or examination of each dietary-ingredient lot (21 CFR 111.75(a)(1)(i)). Two orthogonal methods would be EUTECNIQ's internal standard, not a legal requirement. DNA methods complement chemical methods: a 2018 review recommends using them together with hyphenated chemical methods (Raclariu et al. 2018).
In house or partner: In house (planned, Phase I): microscopy, HPTLC, HPLC, LC-MS. Qualified partners: DNA barcoding and NMR, which are not in the facility phase plan.

03Molecular characterization

In house · Phase ISecond LC-MS · Phase IIPartner · specialist tests

Objective. Measure what the material contains, how much, how it varies between lots and which contaminants it carries.

Measurements: Marker and active compounds; chromatographic fingerprint and untargeted profile; elemental impurities; pesticide residues; residual solvents; mycotoxins; microbial counts; moisture and particle size.
Instruments and models: UHPLC, LC-MS/MS and high-resolution LC-MS, GC-MS, ICP-MS (inductively coupled plasma mass spectrometry for metals), compendial microbiology. Multivariate statistics to model lot-to-lot variability.
Proceed if: Each specification attribute has a method shown to be fit for purpose; composition falls in a range that can be justified as a specification; contaminants are below the proposed limits.
Stop or loop back if: A contaminant exceeds its limit and no practical removal step exists.
Marker variability is too wide to standardize.
No fit-for-purpose method exists for a critical attribute.
Deliverable: Analytical characterization package and draft specifications.
Regulatory limits: Component specifications must cover identity, purity, strength, composition and contaminant limits (21 CFR 111.70(b)), and test methods must be appropriate and scientifically valid (21 CFR 111.320). ISO/IEC 17025 accreditation covers only the tests listed on a laboratory's scope; EUTECNIQ holds none.
In house or partner: In house (planned, Phase I; a second LC-MS in Phase II). Qualified partners: accredited laboratories for tests outside the planned scope and for confirmatory results.

04Safety and interactions

Assessment in housePartner · CROs

Objective. Decide whether the intended dose, population and duration are supported by evidence, and which gaps testing must close.

Measurements and analyses: Exposure estimate from intended use; documented history of use; published toxicology and human data; constituents of concern; enzyme- and transporter-mediated interaction literature; gap analysis.
Instruments and models: Exposure models; benchmark-dose and margin-of-exposure methods where data allow (EFSA 2022); in vitro screens; study designs that follow OECD test guidelines, run by contract research organizations (CROs).
Proceed if: A safety narrative supports the intended conditions of use, or a defined testing plan can close the gaps at a cost the program can bear.
Stop or loop back if: A liver-injury or genotoxicity signal appears at relevant exposure.
A constituent of concern cannot be controlled by specification.
A clinically important interaction risk exists at the intended dose.
Required testing costs more than the commercial case can carry.
Deliverable: Botanical safety dossier (the risk dossier) with a testing plan.
Regulatory limits: FDA's current NDI guidance does not require GLP (Good Laboratory Practice, 21 CFR Part 58) studies; EUTECNIQ would design pivotal toxicology studies to GLP standards where appropriate. Human studies need IRB review and informed consent (21 CFR Parts 50 and 56); a study of disease endpoints needs an IND.
In house or partner: In house (planned): exposure and literature assessment, dossier writing. Qualified partners: toxicology studies at CROs; human studies at clinical research organizations.

05Delivery engineering

Lab scale · Phase IPilot drying · Phase IIPartner · human PK

Objective. Make the ingredient stable and dosable in its target format and, where absorption is the real limit, address that limit with evidence.

Measurements: Solubility and partitioning; chemical stability; droplet or particle size; surface charge; encapsulation efficiency; dissolution; in vitro digestion as a bioaccessibility screen; physical stability over time.
Instruments and models: Homogenizers, emulsification and drying equipment; dynamic light scattering (ISO 22412) and laser diffraction (ISO 13320); dissolution (USP <2040>); INFOGEST digestion (Brodkorb et al. 2019). Models: the lipid formulation classification system (Pouton 2000, 2006) and solubility screening.
Proceed if: The prototype meets physical and chemical stability targets, and a stated mechanism links the delivery system to the identified absorption limit.
Stop or loop back if: Absorption is not limited by solubility or dissolution, so a carrier would add cost without benefit.
Excipient levels are unsuitable for the product category or dose.
The system is physically or chemically unstable.
The process cannot be scaled.
Deliverable: A formulation prototype and a bioavailability and delivery technology dossier.
Regulatory limits: Nanoemulsion stability is not demonstrated bioavailability, and in vitro bioaccessibility is not systemic exposure. For a nanomaterial-modified NDI, FDA's 2026 final guidance says data on the non-nano form alone are unlikely to address nano-specific safety concerns.
In house or partner: In house (planned): laboratory formulation and drying in Phase I, pilot drying in Phase II. Qualified partners: human pharmacokinetic studies and plasma bioanalysis.

06Process scale-up

Lab process · Phase IPilot plant · Phase IIPartner · contract manufacturers

Objective. Show that a larger-scale process makes on-specification material, with its critical parameters known and controlled.

Measurements: Critical process parameters and critical quality attributes; mass and energy balances; yield and purity together; solvent recovery and residual solvent; heat history; batch-to-batch consistency.
Instruments and models: Pilot extraction, evaporation, solvent recovery and pilot drying (Phase II). Mass-transfer and drying models; design of experiments; a cost-of-goods model. See process engineering and scale-up.
Proceed if: Consecutive pilot batches meet specifications under a written control strategy, and each release attribute has a validated method.
Stop or loop back if: Quality attributes drift with scale.
Solvent or energy use is unsafe or uneconomic.
Cost of goods exceeds what the market supports.
No qualified manufacturing capacity is available.
Deliverable: Specifications backed by validated methods, and a process development and transfer package.
Regulatory limits: Supplement manufacture follows 21 CFR Part 111; dietary ingredients sold only to other manufacturers generally follow Part 117. Drug manufacturing (21 CFR Parts 210 and 211) is outside the plan. Flammable-solvent processing needs fire-code review and local permits.
In house or partner: In house (planned): laboratory scale in Phase I, pilot plant in Phase II after its gate. Qualified partners: commercial-scale runs at contract manufacturers until Phase III.

07Regulatory strategy

In housePartner · counsel

Objective. Match the product, its claims and its filings to what the evidence supports, market by market.

Analyses: Classification by intended use (food, supplement, cosmetic or drug); new-dietary-ingredient status; GRAS or food-additive routes for foods; MoCRA obligations for cosmetics; international routes such as EU novel food, Canadian natural health product licensing, Australian listed medicines and Japan's Foods with Function Claims.
Instruments and models: A dated register of rules and their status; a claims matrix; dossier templates aligned with FDA's October 2026 final guidance on NDI identity and safety information.
Proceed if: A pathway exists whose evidence requirements are met or can be met with a defined plan, and the intended claims match the evidence.
Stop or loop back if: The intended claims would make the product a drug.
The ingredient is excluded from the dietary-supplement definition.
Evidence gaps cannot be closed economically.
No lawful route exists in the target market.
Deliverable: A regulatory market-access assessment and, where needed, an NDIN support package that assembles the safety evidence for filing.
Regulatory limits: FDA does not approve NDI notifications, and an acknowledgment without objection is not an FDA finding of safety. GRAS is not the route for supplement ingredients. Cosmetic registration and listing are not approval. Nothing here is legal advice. See regulatory and safety.
In house or partner: In house (planned): regulatory science and dossier assembly. Qualified partners: regulatory counsel and in-country consultants.

08Commercial ingredient, technology or IP

In housePartner · patent counsel, manufacturers

Objective. Turn the evidence into something a customer can buy, license or develop with EUTECNIQ.

Activities: Final specification and certificate-of-analysis format; supply and quality agreements; technology transfer to manufacturers; prior-art landscape and filing decisions; market-access dossiers; distribution.
Instruments and models: Patent and literature searches, ownership mapping under written agreements, a commercial model and a supply plan. See commercialization and licensing.
Proceed if: A customer or partner commits; ownership and data terms are agreed before work starts; counsel has reviewed freedom to operate.
Stop or loop back if: There is no defensible difference from existing products.
Freedom to operate is blocked.
Supply cannot be secured at scale.
Margins do not work.
Deliverable: An IP and commercialization assessment, a commercial specification and a technology-transfer file.
Regulatory limits: Claims in labeling and marketing establish intended use; a disease claim on a supplement makes it subject to regulation as a drug (21 CFR 101.93(f)). EUTECNIQ owns no patents; the founder's patents are assigned to Yazaki.
In house or partner: In house (planned): business development and technical landscaping. Qualified partners: patent counsel, contract manufacturers and distributors.

Sources: 21 CFR 111.70, 111.75, 111.320; 21 CFR 1.511; 21 CFR 101.93; 21 CFR Parts 50, 56 and 58 (eCFR, current to Oct 21, 2026); FDA, NDI identity and safety final guidance (Oct 2026); FDA IND guidance (2013); EFSA Scientific Committee, benchmark dose guidance (2022); Raclariu et al., Phytochem Anal 2018;29:123–128; Brodkorb et al., Nat Protoc 2019;14:991–1014; Pouton, Eur J Pharm Sci 2000 and 2006; CITES; Nagoya Protocol (CBD).

In house or partner

Planned in-house work starts with the laboratory core; specialist studies would go to qualified partners

"In house" means a capability planned for a proposed facility phase. "Partner" means a qualified outside organization under a written agreement; none is signed.

A partner would be qualified once, and every sample and result would be trackedProposed practice

The quality rules behind every stage (21 CFR 111, 21 CFR 117, cosmetic obligations, ISO/IEC 17025) are on the quality system page; the sample route through the proposed building is on the proposed lab journey.

Text version: in-house and partner work by stage, and how a partner would be qualified

Stage	Planned in house	Qualified external partner
1 · Botanical source	Phase I Document review, screening tests	Partner In-country audits and agents
2 · Identity	Phase I Microscopy, HPTLC, HPLC, LC-MS	Partner DNA barcoding, NMR
3 · Characterization	Phase I Chromatography, mass spectrometry, ICP-MS, microbiology; Phase II second LC-MS	Partner Accredited laboratories for out-of-scope or confirmatory tests
4 · Safety and interactions	Phase I Exposure and literature assessment, dossier writing	Partner Toxicology studies (GLP where appropriate); human studies
5 · Delivery engineering	Phase I Laboratory formulation and drying; Phase II pilot drying	Partner Human pharmacokinetic studies, bioanalysis
6 · Process scale-up	Phase I Laboratory process; Phase II pilot plant	Partner Commercial-scale runs at contract manufacturers until Phase III
7 · Regulatory strategy	Phase I Regulatory science, dossier assembly	Partner Regulatory counsel, in-country consultants
8 · Commercial	Phase I Business development, technical landscaping	Partner Patent counsel, contract manufacturers, distributors

How a partner would be qualified

A written quality or service agreement that fixes scope, data ownership and confidentiality.
A check that the partner's accreditation scope or GLP status covers the specific test, not only the laboratory.
An audit, onsite or remote, sized to the risk of the work.
Chain of custody for every sample sent and returned.
Results imported into the lot record and reviewed by EUTECNIQ quality before use.

Proposal

Global ingredients

Global sourcing and distribution would use the same gates to qualify international ingredients for U.S. buyers

From an international supplier to a U.S. buyer, with each party's dutiesProposed function

Importers of dietary-supplement components have Foreign Supplier Verification Program duties under 21 CFR Part 1, Subpart L; the reduced requirements of 21 CFR 1.511(a) and (b) apply only when the importer or its customer is the Part 111 firm that tests the incoming material.eCFR, 21 CFR 1.511 and 111.75, current to Oct 21, 2026.

For international suppliers

Prepare material for U.S. qualification

Supplier pathway →

For U.S. manufacturers

Source with documented qualification

Buyer pathway →

Function overview

Global ingredient sourcing and distribution

Global ingredients →

Laboratory organization

Inside the laboratory, six proposed work cells would carry out the stages

The stages describe decisions; the cells describe where the work would happen. Each cell is defined by what it must establish.

What each work cell would establish, and what it would notProposed organization

Phase I is proposed for 2027; Phases II and III follow only when their gates are met (facilities roadmap). USP <563> botanical identification; USP <2232> elemental contaminants; USP <2021>–<2023> microbiology.eCFR, 21 CFR 111.70, 111.75, 111.87, 111.605 and Parts 11, 117, current to Oct 21, 2026; ICH Q2(R2); ICH Q1A(R2).

Text version of the six work cells

01 · Phase I

Characterize

Establishes: What the material is and what is in it: species and plant-part identity, marker compounds, adulterants, elemental impurities, pesticides and microbes.
Equipment classes: LC-MS/MS, high-resolution LC-MS, HPTLC, ICP-MS, GC-MS.
Rules and standards: 21 CFR 111.75(a)(1) identity testing of every dietary-ingredient lot; USP <563> botanical identification; USP <2232> elemental contaminants.
Does not establish: That the next lot will match.

02 · Phase I–II

Standardize

Establishes: Extraction and separation conditions that hold composition within justified specifications, lot after lot, measured by validated methods.
Equipment classes: Laboratory CO₂ and ethanol–water extraction, preparative LC; pilot extraction, evaporation and solvent recovery in Phase II.
Rules and standards: 21 CFR 111.70 specifications; 21 CFR Part 117 for ingredients sold to manufacturers; ICH Q2(R2) method validation as good practice.
Does not establish: Stability in a finished product.

03 · Phase I–II

Formulate

Establishes: Dispersions, emulsions, encapsulates and dried powders that hold their structure and dose through manufacture and storage.
Equipment classes: High-pressure homogenizers; droplet sizing by dynamic light scattering (ISO 22412) and laser diffraction (ISO 13320); spray, freeze and fluid-bed drying.
Rules and standards: Product specifications and stability data under 21 CFR 111.
Does not establish: Absorption in people.

04 · Phase I

Prove

Establishes: Stability under defined storage, release testing against specifications, microbiology, in vitro digestion as a bioaccessibility screen, and human pharmacokinetics through clinical partners.
Equipment classes: Stability chambers; disintegration and dissolution (USP <2040>); microbiology (USP <2021>–<2023>); INFOGEST in vitro digestion.
Rules and standards: 21 CFR 111.70(e) finished-batch specifications; ICH Q1A(R2) storage conditions as good practice.
Does not establish: Absorption: in vitro digestion screens bioaccessibility only.

05 · Phase II–III

Manufacture

Establishes: Blended, encapsulated and packaged finished supplements, and dietary ingredients for other manufacturers, each released by quality control personnel.
Equipment classes: Blenders, encapsulators, tablet presses, packaging lines; a commercial dryer in Phase III.
Rules and standards: 21 CFR Part 111 for finished supplements (disposition by quality control, 111.87); 21 CFR Part 117 for dietary ingredients; no drug manufacturing.
Does not establish: Fitness to make drugs: Part 111 compliance does not cover drug manufacturing.

06 · Phase I

Learn

Establishes: Structured records of every measurement in a laboratory information management system (LIMS) and electronic notebooks, so models are trained on measured data.
Equipment classes: LIMS, electronic laboratory notebooks, physics-informed models.
Rules and standards: Electronic records required by Part 111 must meet 21 CFR Part 11 (111.605(c)); customer data used only under contract terms.
Does not establish: A validated model: a dataset is not a model, and each model must pass its own gate.

Core equipment

Three equipment classes turn a plant into a specification and a dosable powder

Triple-quadrupole LC-MS/MS in multiple-reaction-monitoring modeIllustrative schematic

Generic operating principle drawn for orientation, not a specific instrument model; no equipment has been selected.

Operating principle, output and limits

Operating principle

The column separates compounds in time; electrospray ionizes them. Q1 passes only the target's precursor mass, the collision cell (q2) fragments it and Q3 passes one characteristic fragment. Only the right mass with the right fragment reaches the detector.

What it delivers

Identity markers, potency, adulterant screens and trace contaminants behind release specifications.

Limits

It finds only what it is set up to find. Untargeted questions need high-resolution MS; identity needs an orthogonal method such as HPTLC.

Co-current spray dryer with cyclone separationIllustrative schematic

Generic operating principle drawn for orientation, not a specific instrument model; no equipment has been selected.

Operating principle, output and limits

Operating principle

A liquid extract or emulsion is atomized into hot air. Evaporation cools each droplet, so the solids stay far cooler than the inlet air while they dry in seconds. A cyclone separates the powder.

What it delivers

Free-flowing powders and encapsulated oils that can be blended, encapsulated or tableted.

Limits

Sugar-rich extracts turn sticky near their glass transition and coat the chamber (Bhandari et al. 1997). Heat-labile actives need inlet and outlet temperature windows proven at pilot scale before commercial runs.

Bhandari BR, Datta N, Howes T. Drying Technol. 1997;15(2):671–684. doi:10.1080/07373939708917253

Shelf freeze-dryer during primary dryingIllustrative schematic

Generic operating principle drawn for orientation, not a specific instrument model; no equipment has been selected.

Operating principle, output and limits

Operating principle

The frozen product sits below the vapor pressure of ice. Shelf heat drives sublimation; vapor deposits on a colder condenser as the sublimation front moves down.

What it delivers

Dry, porous solids for heat-sensitive actives, cultures and extracts.

Limits

Slow and energy-intensive; above its collapse temperature the structure collapses. The science lab calculator shows the pressure and temperature window.

Proposed operating divisions

Seven proposed capability groups would share one quality system and one data layer

None exists today; several would start as programs run with outside laboratories and research organizations.

Seven groups, how each would start, and the two layers they shareProposed organization

Proposed organization of EUTECNIQ Sciences. No group exists yet, and no one besides the founder has been hired.

Text version: mandates, starting mode and where each group is described

Proposed group	Technical and commercial mandate	How it would start	Where it is described
Ingredient Discovery	Botanical screening, phytochemistry, molecular characterization, bioactive discovery, ingredient selection	In house, Phase I laboratory core	Discovery and characterization
Advanced Delivery Technologies	Self-emulsifying and lipid systems, nanoemulsions, encapsulation, controlled release, absorption enhancement	In house at laboratory scale; human studies with partners	Advanced delivery
Regulatory and Safety Sciences	New dietary ingredient notifications, GRAS dossiers for food uses, exposure assessment, toxicology through qualified partners, cross-category strategy	In house assessment; studies with partners	Regulatory and safety
Global Ingredients	International sourcing, U.S. import compliance, supplier qualification, distribution and agency arrangements	In house, with in-country partners	Global ingredients
Formulation and Manufacturing	Supplements, functional foods, beverages, powders, capsules and cosmetics, each in the formats its regulatory category allows	Laboratory scale first; pilot in Phase II; contract manufacturers until Phase III	Process engineering and scale-up
Computational Sciences	Computer-aided molecular design, QSPR and QSAR models, physiologically based pharmacokinetic (PBPK) models, molecular simulation, Bayesian optimization	In house from Phase I	Computational science and AI
IP and Licensing	Ingredient, formulation and process inventions, know-how licensing, development partnerships	After data exist; with patent counsel	Commercialization and licensing

How customers would engage

Four proposed lines of business would fund the platform, with services first

Pharmaceutical partnerships would be separate, regulated programs and are not part of this operating plan.

Services would earn first; ingredients, manufacturing and licensing would followProposal

Proposed lines of business in their proposed order, not forecasts. No service is offered yet and no customer has engaged EUTECNIQ.

Text version of the four lines of business

Analytical testing and contract R&D

Who pays: supplement brands, importers and contract manufacturers.

For: identity, potency, contaminant and stability testing; extraction and formulation projects.

Proposal

Standardized ingredients

Who pays: brands that need documented, consistent inputs.

For: ingredients with justified specifications and a safety dossier, under multiyear supply.

Proposal

Formulation, pilot and contract manufacturing

Who pays: brands outsourcing development and production.

For: development work, pilot lots and supplement manufacturing under 21 CFR Part 111.

Proposal

Licensing of process know-how and models

Who pays: licensees in defined fields of use.

For: process licenses and validated models, only after technical milestones are met.

Proposal

Explanation, details and sources

EUTECNIQ owns no proprietary technology; the founder's patents belong to a prior employer. Any IP would come from project data under ownership rules agreed before work starts, with freedom-to-operate review before each commitment. Investor matters: investor information.

Bring a candidate ingredient or a hard question

Describe the material, the market and the decision you need to make. EUTECNIQ is in formation, so the first conversation is about fit and scope.

Discuss a development question See the deliverables